Polymyxin b


Generic Medicine Info
Contraindications
Hypersensitivity to polymyxins; perforated ear drums (otic). Concurrent use w/ nephrotoxic and/or neurotoxic drugs and neuromuscular blockers.
Special Precautions
Patients w/ pre-existing nitrogen retention. Renal impairment. Pregnancy and lactation. Patient Counselling Eye drop/oint may cause temporary blurred vision or other visual disturbances which may affect ability to drive or operate machinery. Monitoring Parameters Monitor renal function; neurologic symptoms; signs of superinfection.
Adverse Reactions
Facial flushing, fever, rash, pruritus, urticaria, skin exanthema, eosinophilia, dizziness, ataxia; severe pain at inj sites (IM), thrombophlebitis (IV) at inj sites. Ophth: ocular discomfort, keratitis, eye irritation.
Potentially Fatal: Nephrotoxicity, neurotoxicity (higher doses or in patients w/ renal impairment); resp paralysis, anaphylaxis, Clostridium difficile-associated diarrhoea and pseudomembranous colitis.
ROUTE(S) : Otic / Topical: C FDA pregnancy category C applies to polymyxin B in combination w/ other drugs.
ROUTE(S) : Ophth: C FDA pregnancy category C applies to polymyxin B in combination with other drugs.
ATC Classification
A07AA05 - polymyxin B ; Belongs to the class of antibiotics. Used in the treatment of intestinal infections.
S03AA03 - polymyxin B ; Belongs to the class of antiinfectives used in ophthalmologic and otologic preparations.
S02AA11 - polymyxin B ; Belongs to the class of antiinfectives used in the treatment of ear infections.
S01AA18 - polymyxin B ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
J01XB02 - polymyxin B ; Belongs to the class of polymyxins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on polymyxin b from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in